/PRNewswire/ The makers of Senseon® have unveiled their latest access control innovation for the healthcare market in response to the evolving needs of the.
ESSA Pharma Announces Pricing of Public Offering of Common Shares
News provided by
Share this article
Share this article
VANCOUVER, BC and HOUSTON, Feb. 17, 2021 /PRNewswire/ - ESSA Pharma Inc. ( ESSA , or the Company ) (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the pricing of an underwritten public offering of 4,830,918 common shares at a public offering price of $27.00 per share, before underwriting discounts, for an aggregate offering of approximately $130.4 million (the Offering ). ESSA has granted the underwriters a 30-day option to purchase, in whole or in part, up to an additional 724,637 shares of its common shares (the Option ). The proceeds to ESSA from the Offering are expected to be approximately $121.6 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the Option. ESSA intends to u
Mind Cure Comments on Recent Promotional Activity
News provided by
Share this article
Mind Cure or the
Company ) (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) has been asked by OTC Markets Group Inc. (
OTC Markets ) to comment on recent promotional activity concerning its common shares traded on the OTCQB.
On February 11, 2021, OTC Markets sent the Company copies of two articles (the
Articles ) purportedly distributed by National Inflation Association (
NIA ). The Company was not aware of the Articles until the OTC Markets sent a copy of them to the Company on February 11, 2021.
The Company does not believe the promotional activities were a factor in the recent increase in trading volume in the Company s common shares on the OTCQB which occurred beginning on or about February 10, 2021. Instead, the Company attributes the increase to the announcement on February 10, 2021 that the Company closed a C$23 million bought deal offering (the
Share this article
Share this article
OXFORD, England, Feb. 18, 2021 /PRNewswire/ Evox Therapeutics Ltd ( Evox or the Company ), a leading exosome therapeutics company, today announces that it has raised £69.2 million ($95.4 million) in a Series C financing round.
The financing was significantly oversubscribed with high demand from both existing and new investors. The Series C financing was led by Redmile Group who were joined by new investors OrbiMed and Invus. In addition to Redmile, all existing Series B investors reinvested, including major investors Oxford Sciences Innovation (OSI), GV (formerly Google Ventures) and Cowen Healthcare Investments. Eli Lilly, also converted a $10 million convertible note, that formed part of our 2020 collaboration agreement with them, into equity as part of this round.